Close Menu

NEW YORK (360Dx) – High-sensitivity troponin testing continues to make inroads in the US as diagnostic firms bring new high-sensitivity assays to market.

Mathias Egermark, senior VP/lifecycle leader cardiac, women's health, personalized healthcare solutions at Roche, said he expects that essentially all of the company's US troponin T customers will convert to the high-sensitivity version of the assay over the next two to three years.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.